GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (NAS:INSM) » Definitions » Net Issuance of Debt

INSM (Insmed) Net Issuance of Debt : $147.4 Mil (TTM As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Insmed Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Insmed's net issuance of debt for the three months ended in Dec. 2024 was $149.3 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Dec. 2024 was $147.4 Mil.


Insmed Net Issuance of Debt Historical Data

The historical data trend for Insmed's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Net Issuance of Debt Chart

Insmed Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 336.34 349.40 -1.22 147.39

Insmed Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.17 -0.62 -0.65 -0.66 149.31

Insmed Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $147.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Insmed Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Insmed's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Insmed Business Description

Traded in Other Exchanges
Address
700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Executives
William Lewis officer: President & CEO 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Sara Bonstein officer: Chief Financial Officer 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Flammer Martina M.d. officer: Chief Medical Officer 700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Roger Adsett officer: Chief Commercial Officer 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
John Drayton Wise officer: Chief Commercial Officer 700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Michael Alexander Smith officer: General Counsel, Senior VP 700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Schaeffer Orlov S Nicole officer: Chief People Strategy Officer INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Melvin Md Sharoky director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Leo Lee director 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
David R Brennan director C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Steinar J Engelsen director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
John Soriano officer: Chief Compliance Officer 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Christine A Pellizzari officer: General Counsel & Secretary 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Alfred Altomari director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Elizabeth M Anderson director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807